Saturday, February 25, 2023 9:33:24 PM
https://www.alvotech.com/
We have a deep appreciation for the positive impact biologic medicines have had on health care. From insulin to vaccines to monoclonal antibody cancer therapies, biologic medicines are revolutionizing the way we treat diseases and improve patient lives.
It is our aim to broaden the availability of these important biologic medicines to patients around the world by developing and manufacturing high-quality, cost-competitive biosimilars.
Our commitment to the promise of biosimilars is foundational to our approach, our culture and the strong sense of purpose that inspires us to work smarter and faster towards this mission.
We are driven by passion - if there is a proven biologic medicine, we believe it should be accessible to all patients in need.
Recent ALVO News
- Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET • GlobeNewswire Inc. • 10/30/2024 12:30:00 PM
- Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 • GlobeNewswire Inc. • 10/25/2024 12:00:00 PM
- Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) • GlobeNewswire Inc. • 10/22/2024 11:00:00 AM
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® • GlobeNewswire Inc. • 10/10/2024 09:00:00 AM
- Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® • GlobeNewswire Inc. • 09/25/2024 09:00:00 AM
- Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/26/2024 01:14:00 PM
- H&R Block Shares Surge 10% on Profit and Dividend Boost, Applied Materials Drops 3% Despite Strong Earnings, Latest in Earnings • IH Market News • 08/16/2024 09:57:29 AM
- Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 • GlobeNewswire Inc. • 08/15/2024 08:15:00 PM
- U.S. Futures Rise on Easing Inflation, Oil Prices Rise • IH Market News • 08/15/2024 10:09:48 AM
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) • GlobeNewswire Inc. • 08/15/2024 08:30:00 AM
- Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET • GlobeNewswire Inc. • 08/01/2024 08:02:00 PM
- STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe • GlobeNewswire Inc. • 07/22/2024 10:30:00 AM
- Alvotech Announces Closing of Private Debt Financing • GlobeNewswire Inc. • 07/11/2024 08:45:00 AM
- Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® • GlobeNewswire Inc. • 07/02/2024 01:00:00 PM
- Alvotech Issues New Shares to Holders of Convertible Bonds • GlobeNewswire Inc. • 07/01/2024 09:35:00 PM
- Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 • GlobeNewswire Inc. • 07/01/2024 09:10:00 AM
- Alvotech Receives Conversion Notices for Majority of Convertible Bonds • GlobeNewswire Inc. • 06/26/2024 08:50:00 AM
- Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe • GlobeNewswire Inc. • 06/18/2024 08:01:00 AM
- Alvotech and STADA add to strategic alliance through denosumab partnership • GlobeNewswire Inc. • 06/11/2024 08:00:00 AM
- Alvotech Announces Strategic Refinancing Agreement • GlobeNewswire Inc. • 06/07/2024 08:00:00 AM
- Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 • GlobeNewswire Inc. • 05/29/2024 12:05:00 PM
- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update • GlobeNewswire Inc. • 05/21/2024 09:15:00 PM
- Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK • Business Wire • 05/21/2024 02:05:00 PM
- Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK • GlobeNewswire Inc. • 05/21/2024 12:00:09 PM
- U.S. Index Futures Open Lower Amid Nasdaq Record, Fed Speeches • IH Market News • 05/21/2024 11:13:09 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM